# A systems-based approach to uterine fibroids identifies differential splicing associated with abnormal uterine bleeding

**Authors:** Chen-Yi Wang, Martin Philpott, Darragh P O’Brien, Anne Ndungu, Jessica Malzahn, Marina Maritati, Neelam Mehta, Vicki Gamble, Beatriz Martinez-Burgo, Sarah Bonham, Roman Fischer, Kurtis Garbutt, Christian M. Becker, Sanjiv Manek, Adrian L. Harris, Frank Sacher, Maik Obendorf, Nicole Schmidt, Jörg Müller, Thomas M. Zollner, Krina T. Zondervan, Benedikt M. Kessler, Udo Oppermann, Adam P. Cribbs

PMC · DOI: 10.1038/s43856-025-01051-x · Communications Medicine · 2025-07-31

## TL;DR

This study explores how genetic changes in uterine fibroids may cause heavy menstrual bleeding by affecting nearby womb lining tissues.

## Contribution

The study reveals that fibroid mutations influence endometrial RNA splicing, linking genetic changes to abnormal bleeding.

## Key findings

- MED12 mutations in fibroids correlate with altered RNA splicing in the endometrium.
- Variants in AHR and COL4A6 are identified as contributing to fibroid-related symptoms.
- Altered splicing in endometrium is linked to pathways involving angiogenesis and extracellular matrix.

## Abstract

Uterine fibroids (UFs), benign tumours prevalent in up to 80% of women of reproductive age, are associated with significant morbidity, including abnormal uterine bleeding, pain and infertility. Despite identification of key genomic alterations in MED12 and HMGA2, the pathogenic mechanisms underlying UFs and heavy menstrual bleeding (HMB) remain poorly understood.

To correlate systematically genetic, transcriptional and proteomic phenotypes, we conducted an integrative multi-omic approach utilising targeted DNA sequencing, RNA sequencing and proteomic methodologies, encompassing fibroid, myometrium, and endometrium tissues from 91 patients.

In addition to confirming the presence of MED12 mutations, we identify variants in AHR and COL4A6. Multi-omic analysis of endometrium identifies latent factors that correlate with HMB and fibroid presence with driver mutations of MED12, AHR, and COL4A6, which are associated with pathways involved in angiogenesis, extracellular matrix organisation and RNA splicing. We propose a model, supported by in vivo evidence, where altered signalling of MED12-mutated fibroids influences RNA transcript isoform expression in endometrium, potentially leading to abnormal uterine bleeding.

This study presents a comprehensive integrative approach, revealing that genetic alterations in UF may influence endometrial function via signalling impacts on the RNA splicing mechanism. Our findings advance the understanding of complex molecular pathways in UF pathogenesis and UF-associated endometrial dysfunction, offering insights for targeted therapeutic development.

Uterine fibroids are common benign non-cancerous tumours that grow in the womb and affect many women, often causing pain, heavy menstrual bleeding and problems with fertility. Genes are made up of DNA and are inherited. They provide instructions for making proteins and RNA, other molecules within the body. It is known that certain genes are associated with people having fibroids, but how fibroids cause symptoms like heavy menstrual bleeding is still unclear. We examined fibroid and endometrial tissues from 91 women and looked at the DNA, protein and RNA present. We found changes in fibroid tissues and discovered that these changes may also affect nearby endometrial tissues, which line the womb. This can alter how genes and proteins are expressed and may explain why bleeding occurs. These findings provide new insight into how uterine fibroids affect the body and may help develop better treatments to manage symptoms and improve women’s health in the future.

Wang, Philpott et al. perform integrative genomic, transcriptomic and proteomic analyses across fibroid, myometrium, and endometrium tissues to uncover mechanisms underlying uterine fibroid (UF) associated heavy menstrual bleeding. Signalling from MED12-mutated fibroids alters RNA splicing events in the endometrium.

## Linked entities

- **Genes:** MED12 (mediator complex subunit 12) [NCBI Gene 9968], HMGA2 (high mobility group AT-hook 2) [NCBI Gene 8091], AHR (aryl hydrocarbon receptor) [NCBI Gene 196], COL4A6 (collagen type IV alpha 6 chain) [NCBI Gene 1288]

## Full-text entities

- **Genes:** TBXA2R (thromboxane A2 receptor) [NCBI Gene 6915] {aka BDPLT13, TXA2-R}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, GNRH1 (gonadotropin releasing hormone 1) [NCBI Gene 2796] {aka GNRH, GRH, LHRH, LNRH}, Hnrnpa1 (heterogeneous nuclear ribonucleoprotein A1) [NCBI Gene 15382] {aka HDP-1, Hdp, Hnrpa1, hnRNP A1, hnrnp-A1}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, TTF2 (transcription termination factor 2) [NCBI Gene 8458] {aka HuF2, ZGRF6}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, FGFR2 (fibroblast growth factor receptor 2) [NCBI Gene 2263] {aka BBDS, BEK, BFR-1, CD332, CEK3, CFD1}, GEM (GTP binding protein overexpressed in skeletal muscle) [NCBI Gene 2669] {aka KIR}, PTGES (prostaglandin E synthase) [NCBI Gene 9536] {aka MGST-IV, MGST1-L1, MGST1L1, MPGES, PGES, PIG12}, FGF7 (fibroblast growth factor 7) [NCBI Gene 2252] {aka HBGF-7, KGF}, PCOLCE (procollagen C-endopeptidase enhancer) [NCBI Gene 5118] {aka PCPE, PCPE-1, PCPE1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, BMPR2 (bone morphogenetic protein receptor type 2) [NCBI Gene 659] {aka BMPR-II, BMPR3, BMR2, BRK-3, POVD1, PPH1}, Postn (periostin, osteoblast specific factor) [NCBI Gene 50706] {aka A630052E07Rik, OSF-2, Osf2, PLF, PN}, BLNK (B cell linker) [NCBI Gene 29760] {aka AGM4, BASH, BLNK-S, LY57, SLP-65, SLP65}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, RAD51B (RAD51 paralog B) [NCBI Gene 5890] {aka R51H2, RAD51L1, REC2}, TGFB3 (transforming growth factor beta 3) [NCBI Gene 7043] {aka ARVD, ARVD1, LDS5, RNHF, TGF-beta3}, RBM39 (RNA binding motif protein 39) [NCBI Gene 9584] {aka CAPER, CAPERalpha, FSAP59, HCC1, RNPC2}, CAPRIN1 (cell cycle associated protein 1) [NCBI Gene 4076] {aka CONDCAC, GPIAP1, GPIP137, GRIP137, M11S1, NEDLAAD}, COL4A6 (collagen type IV alpha 6 chain) [NCBI Gene 1288] {aka CXDELq22.3, DELXq22.3, DFNX6}, FH (fumarate hydratase) [NCBI Gene 2271] {aka FMRD, HLRCC, HsFH, LRCC, MCL, MCUL1}, HNRNPK (heterogeneous nuclear ribonucleoprotein K) [NCBI Gene 3190] {aka AUKS, CSBP, HNRPK, TUNP}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, TGFB2 (transforming growth factor beta 2) [NCBI Gene 7042] {aka CAEND2, G-TSF, LDS4, TGF-beta2}, HMGA2 (high mobility group AT-hook 2) [NCBI Gene 8091] {aka BABL, HMGI-C, HMGIC, LIPO, SRS5, STQTL9}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, HNRNPC (heterogeneous nuclear ribonucleoprotein C) [NCBI Gene 3183] {aka HNRNP, HNRPC, MRD74, SNRPC}, UCHL1 (ubiquitin C-terminal hydrolase L1) [NCBI Gene 7345] {aka HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5}, RHO (rhodopsin) [NCBI Gene 6010] {aka CSNBAD1, OPN2, RP4}, ANGPT1 (angiopoietin 1) [NCBI Gene 284] {aka AGP1, AGPT, AGPT-1, ANG1, HAE5}, CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}, SRPK1 (SRSF protein kinase 1) [NCBI Gene 6732] {aka SFRSK1}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, Cd59a (CD59a antigen) [NCBI Gene 12509] {aka Cd59, MAC-IP, MACIF}, LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976] {aka CDF, DIA, HILDA, MLPLI}, Acvr1 (activin A receptor, type 1) [NCBI Gene 11477] {aka ALK2, ActR-I, ActRIA, Acvr, Acvr1a, Acvrlk2}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, Mdk (midkine) [NCBI Gene 17242] {aka MK, Mek}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, TGFBR3 (transforming growth factor beta receptor 3) [NCBI Gene 7049] {aka BGCAN, betaglycan}, ANG (angiogenin) [NCBI Gene 283] {aka ALS9, HEL168, RAA1, RNASE4, RNASE5}, BMPR1A (bone morphogenetic protein receptor type 1A) [NCBI Gene 657] {aka 10q23del, ACVRLK3, ALK-3, ALK3, BMPR-1A, CD292}, PTGES2 (prostaglandin E synthase 2) [NCBI Gene 80142] {aka C9orf15, GBF-1, PGES2, mPGES-2}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, PDE1A (phosphodiesterase 1A) [NCBI Gene 5136] {aka CAM-PDE 1A, CAM-PDE-1A, HCAM-1, HCAM1, HSPDE1A}, HMGA1 (high mobility group AT-hook 1) [NCBI Gene 3159] {aka HMG-R, HMGA1A, HMGIY}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Hnrnpc (heterogeneous nuclear ribonucleoprotein C) [NCBI Gene 15381] {aka D14Wsu171e, Hnrpc, Hnrpc1, Hnrpc2, hnRNPC1, hnRNPC2}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, IL11 (interleukin 11) [NCBI Gene 3589] {aka AGIF, IL-11}, BMPR1B (bone morphogenetic protein receptor type 1B) [NCBI Gene 658] {aka ALK-6, ALK6, AMD3, AMDD, BDA1D, BDA2}, HNRNPU (heterogeneous nuclear ribonucleoprotein U) [NCBI Gene 3192] {aka DEE54, EIEE54, GRIP120, HNRNPU-AS1, HNRPU, SAF-A}, MED12 (mediator complex subunit 12) [NCBI Gene 9968] {aka ARC240, CAGH45, FGS1, HDKR, HOPA, Kto}
- **Diseases:** HMB (MESH:D008595), pain (MESH:D010146), endometriosis (MESH:D004715), infertility (MESH:D007246), fibrosis (MESH:D005355), abnormal uterine bleeding (MESH:D014592), urinary incontinence (MESH:D014549), immune dysregulation (OMIM:614878), UF (MESH:D007889), inflammation (MESH:D007249), benign tumours (MESH:D009369), benign tumours of the uterus (MESH:D014594), mycoplasma (MESH:D009175), DTU (MESH:D012734), cervical neoplasia (MESH:D002578), uterine leiomyoma (OMIM:150699), Blood loss (MESH:D016063), anaemia (MESH:D000743), pelvic pain (MESH:D017699), adenomyosis (MESH:D062788), menstrual blood loss (MESH:D004412), ovarian cysts (MESH:D010048), endometrial dysfunction (MESH:D014591), bleeding (MESH:D006470), hereditary leiomyomatosis (MESH:C535516), thrombosis (MESH:D013927), hypoxia (MESH:D000860)
- **Chemicals:** chloroform (MESH:D002725), CaCl2 (MESH:D002122), F-12 (MESH:C007782), 8-Bromoadenosine 3',5'-cyclic monophosphate (MESH:D015124), SDS (MESH:D012967), CHAPS (MESH:C028213), urea (MESH:D014508), E2 (MESH:D004958), steroid (MESH:D013256), isoflurane (MESH:D007530), nitrogen (MESH:D009584), PBS (MESH:D007854), prostaglandin (MESH:D011453), hydroxylamine (MESH:D019811), ammonium hydroxide (MESH:D064753), UPA (MESH:C555622), water (MESH:D014867), Medroxyprogesterone 17-acetate (MESH:D017258), DMSO (MESH:D004121), stainless steel (MESH:D013193), tramadol (MESH:D014147), Trizol (MESH:C411644), formic acid (MESH:C030544), NaOH (MESH:D012972), N-methyl-2-pyrrolidone (MESH:C038678), DAPI (MESH:C007293), MgCl2 (MESH:D015636), ethanol (MESH:D000431), 17alpha-estradiol (MESH:C519808), Poly(A) (MESH:D011061), Thiourea (MESH:D013890), DTT (MESH:D004229), PEG400 (MESH:C000595213), TFA (MESH:D014269), puromycin (MESH:D011691), C (MESH:D002244), P4 (MESH:C015586), DMEDM (-), sesame oil (MESH:D012715), EGCG (MESH:C045651), acetonitrile (MESH:C032159), ACN (MESH:C084683), progesterone (MESH:D011374), methanol (MESH:D000432), NaCl (MESH:D012965), bicarbonate (MESH:D001639), haem (MESH:D006418), TEAB (MESH:C041737), HEPES (MESH:D006531)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs2066853, rs6673988, rs6622312
- **Cell lines:** hTERT — Homo sapiens (Human), Transformed cell line (CVCL_E232), THESC — Homo sapiens (Human), Endometriosis, Telomerase immortalized cell line (CVCL_VS88), HMB — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_B1YH), /c — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_9103), Balb/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12311048/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12311048/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12311048/full.md

---
Source: https://tomesphere.com/paper/PMC12311048